SPRO vs DBVT vs AGEN vs MRK vs ABBV

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -53. 8% for Spero Therapeutics, Inc. (SPRO). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Spero Therapeutics, Inc. (SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, Agenus Inc. is actually cheaper at 1. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 705% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Spero Therapeutics, Inc. (SPRO) carries a lower debt/equity ratio of 9% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -53. 8% for Spero Therapeutics, Inc. (SPRO). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Over a 3-year CAGR, SPRO leads at 150. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -142. 9% for Spero Therapeutics, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 8x forward P/E versus 21. 9x for Merck & Co. , Inc. — 20. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, ABBV (3.

2% yield), MRK (2. 9% yield) pay a dividend. SPRO, DBVT, AGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SPRO is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; AGEN is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; ABBV is a large-cap income-oriented stock. MRK, ABBV pay a dividend while SPRO, DBVT, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.